Mol Med Rep. 2018 Sep 19. doi: 10.3892/mmr.2018.9494. [Epub ahead of print]
Examining the key genes and pathways in hepatocellular carcinoma development from hepatitis B virus‑positive cirrhosis.
Chen QF1, Xia JG2, Li W1, Shen LJ1, Huang T1, Wu P1.
Author information
1
Department of Medical Imaging and Interventional Radiology, Sun Yat‑sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China.
2
Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China.
Abstract
To identify the key genes and pathways in the development of hepatocellular carcinoma (HCC) from hepatitis B virus (HBV)‑positive liver cirrhosis, differentially expressed genes (DEGs) between HCC and liver cirrhosis tissue samples from the GSE17548 gene expression profile dataset were screened. A total of 1,845 DEGs were identified, including 1,803 upregulated and 42 downregulated genes. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein‑protein interaction (PPI) network analyses were performed. It was identified that the 'cell cycle' and 'progesterone‑mediated oocyte maturation' KEGG pathways were significantly enriched in the DEGs. In addition, the high expression of the hub genes from the PPI network (including cyclin dependent kinase 1, cyclin B1, cyclin B2, mitotic arrest deficient 2 like 1, BUB1 mitotic checkpoint serine/threonine kinase and cyclin A2; P=0.00116, 0.00021, 0.04889, 0.00222, 0.00015 and 0.00647, respectively) was associated with a decrease in overall survival for patients with HCC as identified using survival and expression data from The Cancer Genome Atlas. The identified hub genes and pathways may help to elucidate the molecular mechanisms of HCC progression from HBV‑positive liver cirrhosis. Additionally, they may be useful as therapeutic targets or serve as novel biomarkers for HCC prognosis prediction.
为了鉴定乙型肝炎病毒（HBV）阳性肝硬化肝细胞癌（HCC）发展中的关键基因和途径，筛选了来自GSE17548基因表达谱数据集的HCC和肝硬化组织样本之间的差异表达基因（DEG）。 。共鉴定了1,845个DEG，包括1,803个上调基因和42个下调基因。进行了Gene Ontology，Kyoto Encyclopedia of Genes and Genomes（KEGG）和蛋白质 - 蛋白质相互作用（PPI）网络分析。已经确定在DEG中显着富集'细胞周期'和'孕酮介导的卵母细胞成熟'KEGG途径。此外，来自PPI网络的hub基因的高表达（包括细胞周期蛋白依赖性激酶1，细胞周期蛋白B1，细胞周期蛋白B2，有丝分裂停滞缺陷2如1，BUB1有丝分裂检查点丝氨酸/苏氨酸激酶和细胞周期蛋白A2; P = 0.00116,0.00021分别使用0.04889,0.00222,0.00015和0.00647，与使用来自癌症基因组图谱的存活和表达数据鉴定的HCC患者的总存活率降低相关。确定的中枢基因和途径可能有助于阐明HCC从HBV阳性肝硬化进展的分子机制。另外，它们可用作治疗靶标或用作HCC预后预测的新型生物标志物。